| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Fosinopril | Fosinopril EP Impurity A | VL2980003 | View |
| Fosinopril | Fosinopril In house Impurity G | VL2980006 | View |
| Fosinopril | Fosinopril In-house Impurity A | VL2980002 | View |
| Fosinopril | Fosinopril In-house Impurity C | VL2980004 | View |
| Fosinopril | Fosinopril In-house Impurity D | VL2980005 | View |
| Fosinopril | Fosinopril In-house Impurity H | VL2980001 | View |
| Catalogue No. | VL2980003 |
| CAS No. | N/A |
| Molecular Formula | C23H34NO5P |
| Molecular Weight | 435.49 |
| Parent drug | Fosinopril |
| IUPAC Name | (4S)-4-Cyclohexyl-1-[2-[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-L-proline |
| Synonyms | Fosinopril Related Compound A / Fosinopril Diacid /Fosinopril In-house Impurity B / Fosinoprilat |
| References | “Sci-Hub, Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects with Microalbuminuria, 10.1161/01.CIR.0000146378.65439.7A.” Hkvisa.net, 2022, sci-hub.hkvisa.net/10.1161/01.CIR.0000146378.65439.7A. |
| Status | In-stock |
| ListName | Fosinopril EP Impurity A |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
